Chikaraishi T, Sasaki H, Tsutsumi H, Miyano S, Nakazawa R, Nakano T, Kitajima K, Kudo H, Takahashi T, Sato Y, Kimura K
Department of Urology, St. Marianna University, Kawasaki, Kanagawa, Japan.
Transplant Proc. 2008 Dec;40(10):3445-7. doi: 10.1016/j.transproceed.2008.06.110.
We have designed a protocol for ABO-incompatible kidney transplantations based on preoperative plasmapheresis with a tacrolimus/mycophenolate mofetil/methylprednisolone/basiliximab protocol using low-dose rituximab (200 mg/body) instead of splenectomy to prevent antibody-mediated acute rejection. Eight patients successfully received transplants with this protocol. The titers of anti-A and -B antibodies as well as the number of CD20(+) cells were readily maintained at a low level posttransplantation. There were no side effects. All patients have renal transplant function with a follow-up of 1-34 months.
我们设计了一种ABO血型不相容肾移植方案，该方案基于术前血浆置换，并采用他克莫司/霉酚酸酯/甲泼尼龙/巴利昔单抗方案，使用低剂量利妥昔单抗（200mg/体）替代脾切除术以预防抗体介导的急性排斥反应。8例患者采用该方案成功接受了移植。移植后抗A和抗B抗体滴度以及CD20(+)细胞数量很容易维持在低水平。未出现副作用。所有患者均具有肾移植功能，随访时间为1 - 34个月。
